~~<i id='88807441E0'><strike id='88807441E0'><tt id='88807441E0'><pre id='88807441E0'></pre></tt></strike></i>~~

Home» leisure time» entertainment

entertainment

author：leisure time 2025-10-06 06:16:55 Page View：7636

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As the dark side of IVF slowly comes into focus, even more transparency is needed
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

focus

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Illumina slashes 2023 revenue projections yet again

AdobeSANDIEGO—Afterstartingofftheyearwithlowerrevenueprojectionsthanmarketanalystshadhopedfor,SanDie

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

1:02BryanKohbergerentersthecourtroomforahearingattheLatahCountyCourthouseonJune27,2023,inMoscow,Idah